These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31884738)

  • 1. Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.
    Jang HN; Yang YS; Lee SO; Oh TJ; Koo BK; Jung HS
    Endocrinol Metab (Seoul); 2019 Dec; 34(4):382-389. PubMed ID: 31884738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
    Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
    J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
    Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
    Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus.
    Kang S; Ahn YB; Oh TK; Lee WY; Chun SW; Bae B; Dahaoui A; Jeong JS; Jung S; Jang HC
    Diabetes Metab J; 2024 Sep; 48(5):929-936. PubMed ID: 38410023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
    Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
    Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
    Jammah AA
    Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
    Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
    Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS.
    Gerety G; Bebakar WM; Chaykin L; Ozkaya M; Macura S; Hersløv ML; Behnke T
    Endocr Pract; 2016 May; 22(5):546-54. PubMed ID: 26720250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiating or switching to insulin degludec/insulin aspart in a real-world population of adults with type 2 diabetes in Australia: results from a prospective, non-interventional study.
    Fulcher GR; Cohen ND; Davies K; d'Emden M; Glastras SJ; Mah PM; McCallum RW; Moses R; Thong KY; Roberts A
    Intern Med J; 2024 Oct; 54(10):1626-1633. PubMed ID: 39171857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
    Kumar S; Jang HC; Demirağ NG; Skjøth TV; Endahl L; Bode B
    Diabet Med; 2017 Feb; 34(2):180-188. PubMed ID: 27027878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
    Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
    Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
    Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
    Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of Clinical Trial Program and Applicability of Insulin Degludec/Insulin Aspart in Diabetes Management.
    Bantwal G; Wangnoo SK; Shunmugavelu M; Nallaperumal S; Harsha KP; Bhattacharyya A
    J Assoc Physicians India; 2015 May; 63(5 Suppl):21-8. PubMed ID: 26548031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.